Halofantrine

CHEMBL1107 Phase 4 ได้รับการอนุมัติ Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

500.4 g/mol

LogP

8.6

Phase

4

An antimalarial medication used to treat malaria caused by chloroquine-resistant Plasmodium falciparum and P. vivax strains. It works by interfering with the parasite's heme detoxification process, leading to the accumulation of toxic heme within the parasite. Concerns about cardiotoxicity, particularly QT prolongation, limit its use to situations where safer alternatives are not available.

น้ำหนักโมเลกุล

500.4000 g/mol

LogP

8.60

TPSA

23.50 Å²

Lipinski RO5

ไม่ผ่าน

ด้านการรักษา

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Glaucoma Cardiovascular Disease Pain Management Non-Small Cell Lung Cancer Schizophrenia Generalized Anxiety Disorder Systemic Lupus Erythematosus Obesity Transplant Medicine Hypertension Major Depressive Disorder Breast Cancer Malaria HIV/AIDS Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure

Embed this structure

SMILES

CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12

InChI

InChI=1S/C26H30Cl2F3NO/c1-3-5-10-32(11-6-4-2)12-9-25(33)23-16-22-21(14-18(27)15-24(22)28)20-13-17(26(29,30)31)7-8-19(20)23/h7-8,13-16,25,33H,3-6,9-12H2,1-2H3

Molecular Formula

C26H30Cl2F3NO

HBD / HBA

1 / 5

พันธะที่หมุนได้

10

อะตอมหนัก

33

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

An antimalarial medication used to treat malaria caused by chloroquine-resistant Plasmodium falciparum and P. vivax strains. It works by interfering with the parasite's heme detoxification process, leading to the accumulation of toxic heme within the parasite. Concerns about cardiotoxicity, particularly QT prolongation, limit its use to situations where safer alternatives are not available.

Yes, Halofantrine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1107. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 37393. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

กำลังมองหาข้อมูลที่เข้าใจง่ายสำหรับผู้ป่วยอยู่ใช่ไหม?

Halofantrine บน PillFYI

โครงสร้าง

ข้อมูลด่วน

สูตร: C26H30Cl2F3NO

ลิงก์ภายนอก

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.